Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing CpG oligonucleotide

A technology of oligonucleotides and compositions, applied in the field of pharmaceutical compositions, can solve the problems of inability to stimulate Th1 activity, inability to enhance cellular immunity, and hiding of hepatitis B virus

Inactive Publication Date: 2016-01-06
CHANGCHUN HUAPU BIOTECHNOLOGY CO LTD
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, with the development of vaccinology and immunology in recent years, its limitations have been found: aluminum hydroxide mainly stimulates the production of Th2-related antibodies (including IgE), but cannot induce Th1 cell immune responses, cannot stimulate Th1 activity, and cannot enhance Cellular immunity (CTL), blocking the activation of CD8+ CTL
Although this antibody can neutralize the virus outside the cell, it cannot completely remove the hepatitis B virus hidden in the infected cells, which often leads to the hiding of the hepatitis B virus in the patient's body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing CpG oligonucleotide
  • Pharmaceutical composition containing CpG oligonucleotide
  • Pharmaceutical composition containing CpG oligonucleotide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Example 1: Drugs comprising hepatitis B surface antigen (HBsAg) and aluminum hydroxide and CpG oligonucleotides combination

[0079] This embodiment provides a pharmaceutical composition comprising hepatitis B surface antigen (HBsAg), aluminum hydroxide and CpG oligonucleotides, HBsAg, Al(OH) in the pharmaceutical composition 3 and CpG-ODN concentrations are shown in Table 1 below.

[0080] Table 1

[0081] Sample serial number#

HBsAg (μg / ml)

Al(OH) 3 (μg / ml)

CpG (μg / ml)

1#

20

25

0

2#

20

25

25

3#

20

25

125

4#

20

25

500

5#

20

125

0

6#

20

125

25

7#

20

125

125

8#

20

125

500

9#

20

500

0

10#

20

500

25

11#

20

500

125

12#

20

500

500

[0082] 13#

PBS

PBS

PBS

[0083] Detect HBsAg, Al(OH) co...

Embodiment 2

[0103] Example 2: Pharmaceutical composition comprising hepatitis B surface antigen, aluminum hydroxide adjuvant and CpG oligonucleotide Induce antibody to produce immune response

[0104] This embodiment provides a pharmaceutical composition comprising hepatitis B surface antigen (HBsAg), aluminum hydroxide and CpG oligonucleotides, HBsAg, Al(OH) in the pharmaceutical composition 3 and CpG-ODN concentrations are shown in Table 2 below.

[0105] Table 2

[0106] Sample serial number#

HbsAg (μg / ml)

Al(OH) 3 (μg / ml)

CpG (μg / ml)

1#

20

300

125

2#

20

300

250

3#

20

300

500

4#

20

400

125

5#

20

400

250

6#

20

400

500

[0107] 7#

20

500

125

8#

20

500

250

9#

20

500

500

10#

20

500

PBS

[0108] Detect HBsAg, Al(OH) containing the different concentrations liste...

Embodiment 3

[0120] Example 3: Synergistic effect of aluminum hydroxide and CpG oligonucleotides at different concentrations

[0121] This embodiment provides a pharmaceutical composition comprising hepatitis B surface antigen (HBsAg), aluminum hydroxide and CpG oligonucleotides, HBsAg, Al(OH) in the pharmaceutical composition 3 and CpG-ODN concentrations are shown in Table 3 below.

[0122] table 3

[0123] Sample serial number#

HBsAg (μg / ml)

Al(OH) 3 (μg / ml)

CpG (μg / ml)

1#

20

300

125

2#

20

300

250

3#

20

300

500

4#

20

400

125

5#

20

400

250

6#

20

400

500

7#

20

500

125

8#

20

500

250

[0124] 9#

20

500

500

10#

20

500

PBS

[0125] Detect HBsAg, Al(OH) containing the different concentrations listed in Table 3 in the present embodiment according to the experimental...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for inducing immunoreaction in a subject's body. The pharmaceutical composition comprises 1 Mug / ml to 100 Mug / ml of an antigen (a), 25 Mug / ml to 500 Mug / ml of CpG oligonucleotide containing a sequence 5'-tcgacgttcgtcgttcgtcgttc-3', and 25 Mug / ml to 500 Mug / ml of an aluminum adjuvant (c). The pharmaceutical composition may induce or enhance the immunoreaction for antigens, in the subject's body.

Description

technical field [0001] The present invention generally relates to a pharmaceutical composition containing a CpG oligonucleotide, in particular, the present invention relates to a pharmaceutical combination for enhancing immune response against an antigen based on the synergistic effect of a CpG oligonucleotide and an aluminum adjuvant thing. Background technique [0002] Hepatitis B virus (HBV) is a major global problem that endangers public health. The use of vaccines can effectively prevent HBV infection, reduce the carrier rate of chronic hepatitis, and control the prevalence of hepatitis B. According to WTO reports, since 1982, the world has used 1 billion doses of hepatitis B virus vaccine, which has played a very important role in preventing and controlling the spread of hepatitis B virus. Because HBV adopts error-prone RNA-based replication, HBV resistance escape mutants with altered hepatitis B surface antigen (HBsAg) appear. At present, the preventive hepatitis B ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/29A61P31/14A61P31/20
CPCA61K2039/55561A61K2039/55505A61K39/12A61P31/20C12N2730/10134A61K2039/572A61K2039/575A61K39/29A61K39/292A61K39/39A61K2039/54A61K2039/545C12N7/00
Inventor 王立公钱大鹏
Owner CHANGCHUN HUAPU BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com